Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Marketing authorisation indication

Ixazomib citrate (Ninlaro, Takeda), in combination with lenalidomide and dexamethasone, has a marketing authorisation for 'the treatment of adult patients with multiple myeloma who have had at least 1 previous therapy'.

Dosage in the marketing authorisation

Oral capsules, 4 mg once a week on days 1, 8, and 15 of a 28-day cycle. Taken with lenalidomide 25 mg daily on days 1 to 21 of the cycle and dexamethasone 40 mg on days 1, 8, 15, and 22 of the cycle.

Price

£6,336 per cycle (3 capsules, excluding VAT; NHS Dictionary of Medicines and Devices [accessed November 2017]).

As part of the managed access agreement, the company has a commercial access agreement with NHS England. This makes ixazomib available at a reduced cost. The financial terms of the agreement are commercial in confidence.